Why Is Abivax Stock Trading Higher On Monday?

Core Insights - Abivax SA presented additional clinical data for obefazimod at the United European Gastroenterology Meeting, focusing on its efficacy for moderate-to-severely active ulcerative colitis [1][5] - The Phase 3 ABTECT trials demonstrated significant clinical response rates and safety profiles for obefazimod, indicating potential for market approval [2][4] Group 1: Efficacy Data - In the pooled ABTECT 1 & 2 trials, obefazimod 50mg achieved a placebo-adjusted clinical response improvement of 28% in patients without prior advanced therapy inadequate response (AT-IR) and 29% in those with up to four prior AT-IR [2] - The treatment also showed a 34% placebo-adjusted clinical response in participants who previously failed JAK inhibitor therapy, along with significant improvements in endoscopic and histologic endpoints [3] - The 50mg once-daily dose met the FDA primary endpoint of clinical remission at Week 8, with ABTECT-1 showing a 19.3% and ABTECT-2 showing a 13.4% placebo-adjusted clinical remission rate [5][6] Group 2: Safety Profile - Obefazimod was well-tolerated, with no new safety signals identified, and no serious, severe, or opportunistic infections or malignancies reported [4][5] - Both 25mg and 50mg doses demonstrated similar efficacy across clinical, endoscopic, and histological endpoints in participants without prior AT-IR [4] Group 3: Market Reaction - Following the positive data release, Abivax's stock price increased by 5.71%, reaching $88.72 [6]